12-Month Weight Loss Doesn't Differ With Low-Fat, Carb Diets

Share this content:
12-Month Weight Loss Doesn't Differ With Low-Fat, Carb Diets
12-Month Weight Loss Doesn't Differ With Low-Fat, Carb Diets

TUESDAY, Feb. 20, 2018 (HealthDay News) -- Weight change over 12 months does not differ for a healthy low-fat (HLF) diet or a healthy low-carbohydrate (HLC) diet, according to a study published in the Feb. 20 issue of the Journal of the American Medical Association.

Christopher D. Gardner, Ph.D., from the Stanford University Medical School in California, and colleagues examined the impact of a HLF versus a HLC diet on weight change in a randomized trial involving adults aged 18 to 50 years without diabetes with a body mass index between 28 and 40 kg/m². Participants were randomized to HLF (305 adults) or HLC (304 adults); the behavior modification intervention was delivered via 22 diet-specific small group sessions administered over 12 months.

The researchers found that the mean 12-month macronutrient distributions were 48 versus 30 percent for carbohydrates, 29 versus 45 percent for fat, and 21 versus 23 percent for protein in the HLF versus HLC diets. At 12 months, weight change was −5.3 and −6.0 kg for the HLF and HLC diets, respectively (mean between-group difference, 0.7 kg; 95 percent confidence interval, −0.2 to 1.6 kg). No significant diet-genotype pattern interaction or diet-insulin secretion interaction was seen with 12-month weight loss. Eighteen adverse or serious adverse events occurred; these were distributed evenly between the groups.

"In this 12-month weight loss diet study, there was no significant difference in weight change between a healthy low-fat diet versus a healthy low-carbohydrate diet," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »